|
|
Switzerland Pharmaceuticals and Healthcare Report Q1 2008Published by: Business Monitor International Published: Feb. 20, 2008 - 79 Pages Table of Contents
AbstractSwitzerland has an advanced pharmaceutical market and per-capita expenditure is among the highest inthe world at an estimated US$743.4 in 2006. Consumption centres around patented pharmaceuticals, withSwitzerland providing a ready market for cutting-edge therapies. Meanwhile, high-levels of out-of-pocketexpenditure have resulted in the development of a mature and competitive consumer health sector.Overall market growth should expand at a CAGR of 5.73% over the forecast period to reach a value ofUS$7.69bn.In the latest quarter, most market activity has been centred around the major domestic players, withNovartis having an especially busy few months. The multinational has recently announced restructuringplans involving shedding 2,500 jobs, or 2.5% of its workforce, as it hopes to achieve savings of US$1.6bna year until 2010. Meanwhile, Sandoz, Novartis’ generics arm has announced that it is to launch a genericversion of biotech anaemia treatment epoetin alfa (EPO), the primary ingredient in US-based Amgen'sblockbuster Epogen. BMI's views the launch as a major step forward for the rapidly growing biosimilarsindustry. In terms of M&A activity, the major deal saw Swiss pharmaceutical producer and wholesaler Galenicaacquire Canadian biotech Aspreva in a deal worth US$900mn. The purchase is one of the largest ever inthe Canadian pharmaceutical sector and has provided a ringing endorsement for Canada's biotechindustry, often criticised as a difficult environment to work in, while also highlighting the continualinterest of the major Swiss players in snapping up biotech assets. Meanwhile, Switzerland takes first place in BMI’s revised Business Environment Rankings for theWestern European region. We have completely overhauled the methodology giving greater weight toregulatory factors affecting the drug market, while utilising a more nuanced analysis of country-specificeconomic and political factors. Switzerland’s position derives mainly from its excellent regulatory systemand high per-capita expenditure. Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||